# US 2020/0370016 A1 · Methods of generating enucleated erythroid cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0370016 A1
- Document ID: US20200370016A1
- Status: Published application
- Kind: A1
- Application number: 16/882,099
- Filed: 2020-05-22
- Published: 2020-11-26
- Earliest claimed: 2019-05-24
- Assignees: Rubius Therapeutics, Inc.
- Applicants: Rubius Therapeutics, Inc.
- Inventors: Jonathan Lipsitz; Brian Joseph Pereira; Bryan Wang; Alan Gilbert
- Web page: https://patentgrep.com/patent/US20200370016A1

## CPC

- C12N 5/0641: {Erythrocytes}
- C12M 23/08: {Flask, bottle or test tube}
- C12M 23/14: {Bags}
- C12M 27/00: {Means for mixing, agitating or circulating fluids in the vessel (by introduction of gas C12M29/06, C12M29/14, mixing in general or mixers per se B01F; mixing in apparatus for chemical or physical processes B01J)}
- C12M 29/10: {Perfusion}
- C12M 35/04: {Mechanical means, e.g. sonic waves, stretching forces, pressure or shear stimuli}
- C12M 41/32: {of substances in solution}
- C12N 5/0018: {Culture media for cell or tissue culture (media for specific animal cell type C12N5/06)}
- C12N 2500/25: Insulin-transferrin; Insulin-transferrin-selenium
- C12N 2500/33: other than alpha-amino carboxylic acids, e.g. beta-amino acids, taurine
- C12N 2500/36: Lipids
- C12N 2501/125: Stem cell factor [SCF], c-kit ligand [KL]
- C12N 2501/14: Erythropoietin [EPO]
- C12N 2501/2303: Interleukin-3 (IL-3)
- C12N 2501/2306: Interleukin-6 (IL-6)
- C12N 2501/26: Flt-3 ligand (CD135L, flk-2 ligand)
- C12N 2501/39: Steroid hormones
- C12N 2511/00: Cells for large scale production
- C12N 2521/00: Culture process characterised by the use of hydrostatic pressure, flow or shear forces
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12M: APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; {APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS}

## Abstract

Provided herein are methods of generating a population of enucleated erythroid cells.

## Claims

### Claim 1

A method of generating a population of enucleated erythroid cells, the method comprising:
(a) disposing a volume of a first cell culture of erythroid progenitor cells into a second culture medium comprised within a perfusion bioreactor to provide a second cell culture with an initial cell density of about 0.1×105 cells/mL to about 1×107 cells/mL;
(b) perfusion culturing the second cell culture for about 2 days to about 15 days;
(c) disposing a volume of the second cell culture of step (b) into a third culture medium comprised within a perfusion bioreactor to provide a third cell culture with an initial cell density of about 1×105 to about 1×107 cells/mL;
(d) perfusion culturing the third cell culture of step (c) for about 5 days to 20 days, wherein after step (d) the third culture medium comprises a population of enucleated erythroid cells.

### Claim 2 (depends on 1)

The method of claim 1, wherein the method further comprises prior to step (a):
(i) disposing a plurality of erythroid progenitor cells in a first culture medium comprised within a vessel to provide the first cell culture with an initial cell density of about of about 0.1×105 cells/mL to about 2×106 cells/mL; and
(ii) batch or fed batch culturing the first cell culture for about 1 day to about 15 days.

### Claim 3 (depends on 2)

The method of claim 2, wherein the vessel in step (i) is a shake flask, a shake tube, or a culture bag.

### Claim at position 4

-21. (canceled)

### Claim 22 (depends on 2)

The method of claim 2, wherein step (ii) comprises batch culturing the first cell culture.

### Claim 23 (depends on 2)

The method of claim 2, wherein step (ii) comprises fed batch culturing the first cell culture.

### Claim 24 (depends on 23)

The method of claim 23, wherein fed batch culturing comprises adding an additional volume of the first culture medium to the first cell culture over time.

### Claim at position 8

-26. (canceled)

### Claim 27 (depends on 2)

The method of claim 2, wherein the first culture medium comprises one or more of Flt-3 ligand, stem cell factor (SCF), IL-3, and IL-6.

### Claim at position 10

-35. (canceled)

### Claim 36 (depends on 2)

The method of claim 2, wherein the first culture medium further comprises about 1 μg/mL to about 20 μg/mL insulin.

### Claim 37

(canceled)

### Claim 38 (depends on 2)

The method of claim 2, wherein the first culture medium comprises about 1 mM to about 10 mM of L-glutamine, L-alanyl-L-glutamine, L-glycyl-L-glutamine, N-acetyl-L-glutamine, or a combination thereof.

### Claim at position 14

-42. (canceled)

### Claim 43 (depends on 2)

The method of claim 2, wherein the first culture medium comprises lipid.

### Claim 44 (depends on 2)

The method of claim 2, wherein the first culture medium comprises about 50 μg/mL to about 400 μg/mL transferrin.

### Claim at position 17

-60. (canceled)

### Claim 61 (depends on 1)

The method of claim 1, wherein the perfusion culturing in step (b) comprises adding an additional volume of the second culture medium to the second cell culture over time.

### Claim at position 19

-63. (canceled)

### Claim 64 (depends on 1)

The method of claim 1, wherein the second culture medium comprises one or more of: transferrin, IL-3, SCF, dexamethasone, erythropoietin (EPO), and insulin.

### Claim at position 21

-82. (canceled)

### Claim 83 (depends on 1)

The method of claim 1, wherein the second culture medium comprises about 1 mM to about 10 mM of L-glutamine, L-alanyl-L-glutamine, L-glycyl-L-glutamine, N-acetyl-L-glutamine, or a combination thereof.

### Claim at position 23

-87. (canceled)

### Claim 88 (depends on 1)

The method of claim 1, wherein the second culture medium comprises lipid.

### Claim at position 25

-101. (canceled)

### Claim 102 (depends on 1)

The method of claim 1, wherein the perfusion culturing in step (d) comprises:
(i) adding an additional volume of the third culture medium to the third cell culture for a first period of time, and
(ii) adding an additional volume of a fourth culture medium to the third cell culture for a second period of time.

### Claim at position 27

-108. (canceled)

### Claim 109 (depends on 1)

The method of claim 1, wherein the third culture medium comprises one or more of: transferrin, insulin, SCF, and EPO.

### Claim at position 29

-121. (canceled)

### Claim 122 (depends on 1)

The method of claim 1, wherein the third culture medium comprises about 1 mM to about 8 mM of L-glutamine, L-alanyl-L-glutamine, L-glycyl-L-glutamine, N-acetyl-L-glutamine, or a combination thereof.

### Claim at position 31

-125. (canceled)

### Claim 126 (depends on 1)

The method of claim 1, wherein the third culture medium comprises about 0.5% v/v to about 10% v/v serum.

### Claim 127

(canceled)

### Claim 128 (depends on 102)

The method of claim 102, wherein the fourth culture medium comprises one or more of: transferrin, insulin, and EPO.

### Claim at position 35

-137. (canceled)

### Claim 138 (depends on 102)

The method of claim 102, wherein the fourth culture medium comprises about 1 mM to about 8 mM of L-glutamine, L-alanyl-L-glutamine, L-glycyl-L-glutamine, N-acetyl-L-glutamine, or a combination thereof.

### Claim at position 37

-141. (canceled)

### Claim 142 (depends on 102)

The method of claim 102, wherein the fourth culture medium comprises about 0.5% v/v to about 10% v/v serum.

### Claim at position 39

-154. (canceled)

### Claim 155

A method of generating a population of enucleated erythroid cells, the method comprising:
(a) disposing a volume of a first cell culture of erythroid progenitor cells into a second culture medium comprised within a vessel to provide a second cell culture with an initial cell density of about 0.1×105 cells/mL to about 1×107 cells/mL;
(b) batch or fed batch culturing the second cell culture for about 2 days to about 15 days;
(c) disposing a volume of the second cell culture of step (b) into a third culture medium comprised within a perfusion bioreactor to provide a third cell culture with an initial cell density of about 1×105 to about 1×107 cells/mL;
(d) perfusion culturing the third cell culture of step (c) for about 5 days to 20 days, wherein after step (d) the third culture medium comprises a population of enucleated erythroid cells.

### Claim at position 41

-327. (canceled)

### Claim 328

A method of generating a population of enucleated erythroid cells, the method comprising:
(a) disposing a volume of a first cell culture of erythroid progenitor cells into a second culture medium comprised within a perfusion bioreactor to provide a second cell culture with an initial cell density of about 0.1×105 cells/mL to about 1×107 cells/mL;
(b) perfusion culturing the second cell culture for about 2 days to about 15 days;
(c) disposing a volume of the second cell culture of step (b) into a third culture medium comprised within a vessel to provide a third cell culture with an initial cell density of about 1×105 to about 1×107 cells/mL;
(d) batch or fed batch culturing the third cell culture of step (c) for about 5 days to 20 days,
wherein after step (d) the third culture medium comprises a population of enucleated erythroid cells.

### Claim at position 43

-510. (canceled)

### Claim 511 (depends on 1)

The method of claim 1, wherein:
the method further comprises, prior to step (a), introducing a nucleic acid into the erythroid progenitor cells in the first cell culture, and
the method results in the production of a population of engineered enucleated erythroid cells.

### Claim 512 (depends on 511)

The method of claim 511, wherein the population of engineered enucleated erythroid cells are engineered enucleated human erythroid cells.

### Claim 513

(canceled)

### Claim 514 (depends on 511)

The method of claim 511, wherein the engineered human enucleated erythroid cells comprise one or more exogenous protein (s).

### Claim at position 48

-522. (canceled)

### Claim 523 (depends on 511)

The method of claim 511, wherein the method further comprises:
(e) isolating the population of engineered enucleated erythroid cells from the third cell culture in step (d).

### Claim 524 (depends on 523)

The method of claim 523, wherein the method further comprises:
(f) formulating the population of engineered enucleated erythroid cells isolated in step (e).

### Claim 525 (depends on 524)

The method of claim 524, wherein the method further comprises:
(g) administering the formulated population of engineered enucleated erythroid cells in step (f) to a subject in need thereof.

### Claim at position 52

-527. (canceled)

### Claim 528 (depends on 511)

A population of enucleated erythroid cells produced by the method of claim 511.

### Claim 529 (depends on 524)

A formulation produced by the method of claim 524.
